Cryofocus Medtech (Shanghai) (HKG:6922) has obtained approval for its Malignant Stenosis Cryoablation System from China's National Medical Products Administration, a Thursday filing with the Hong Kong bourse said.
The product is a self-developed cryoablation system indicated to ablate malignant airway tumor tissue and reduce the frequency of airway restenosis, according to the medical device company.
Price (HKD): $4.83, Change: $-0.15, Percent Change: -3.01%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。